Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Am J Med Genet A. 2023 Aug;191(8):2015-2044. doi: 10.1002/ajmg.a.63312. Epub 2023 Jul 1.
Phelan-McDermid syndrome (PMS) is a genetic condition caused by SHANK3 haploinsufficiency and characterized by a wide range of neurodevelopmental and systemic manifestations. The first practice parameters for assessment and monitoring in individuals with PMS were published in 2014; recently, knowledge about PMS has grown significantly based on data from longitudinal phenotyping studies and large-scale genotype-phenotype investigations. The objective of these updated clinical management guidelines was to: (1) reflect the latest in knowledge in PMS and (2) provide guidance for clinicians, researchers, and the general community. A taskforce was established with clinical experts in PMS and representatives from the parent community. Experts joined subgroups based on their areas of specialty, including genetics, neurology, neurodevelopment, gastroenterology, primary care, physiatry, nephrology, endocrinology, cardiology, gynecology, and dentistry. Taskforce members convened regularly between 2021 and 2022 and produced specialty-specific guidelines based on iterative feedback and discussion. Taskforce leaders then established consensus within their respective specialty group and harmonized the guidelines. The knowledge gained over the past decade allows for improved guidelines to assess and monitor individuals with PMS. Since there is limited evidence specific to PMS, intervention mostly follows general guidelines for treating individuals with developmental disorders. Significant evidence has been amassed to guide the management of comorbid neuropsychiatric conditions in PMS, albeit mainly from caregiver report and the experience of clinical experts. These updated consensus guidelines on the management of PMS represent an advance for the field and will improve care in the community. Several areas for future research are also highlighted and will contribute to subsequent updates with more refined and specific recommendations as new knowledge accumulates.
佩兰-麦克德米德综合征(PMS)是一种由 SHANK3 单倍不足引起的遗传疾病,其特征是广泛的神经发育和系统表现。2014 年首次发表了针对 PMS 个体评估和监测的实践参数;最近,基于纵向表型研究和大规模基因型-表型调查的数据,人们对 PMS 的认识有了显著提高。这些更新的临床管理指南的目的是:(1)反映 PMS 的最新知识;(2)为临床医生、研究人员和普通社区提供指导。成立了一个由 PMS 临床专家和家长社区代表组成的工作组。专家根据其专业领域加入了不同的小组,包括遗传学、神经病学、神经发育学、胃肠病学、初级保健、物理治疗学、肾脏病学、内分泌学、心脏病学、妇科学和牙科学。工作组成员在 2021 年至 2022 年期间定期开会,并根据迭代反馈和讨论制定了专业特定的指南。然后,工作组领导在各自的专业组内达成共识,并协调了指南。过去十年中获得的知识使我们能够改进评估和监测 PMS 个体的指南。由于针对 PMS 的具体证据有限,干预措施主要遵循针对发育障碍个体的一般指南。虽然主要来自照顾者的报告和临床专家的经验,但已经积累了大量的证据来指导 PMS 中合并的神经精神疾病的管理。这些更新的 PMS 管理共识指南代表了该领域的一项进展,将改善社区中的护理。还强调了几个未来研究领域,随着新知识的积累,这些领域将有助于随后的更新,并提出更精细和具体的建议。